Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

Klotz L, Toren P.

Curr Oncol. 2012 Dec;19(Suppl 3):S13-21. doi: 10.3747/co.19.1298.

2.

Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.

Klotz L.

Curr Urol Rep. 2013 Jun;14(3):159-67. doi: 10.1007/s11934-013-0325-x. Review.

PMID:
23700095
3.

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.

Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, Fradet V, Turgeon AF.

JAMA Oncol. 2015 Dec;1(9):1261-9. doi: 10.1001/jamaoncol.2015.2895. Review.

PMID:
26378418
4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group..

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

6.

Hormone therapy for patients with prostate carcinoma.

Klotz L.

Cancer. 2000 Jun 15;88(12 Suppl):3009-14. Review.

PMID:
10898345
7.

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group..

J Urol. 2012 Jun;187(6):2074-81. doi: 10.1016/j.juro.2012.01.122. Epub 2012 Apr 11.

PMID:
22498230
9.

Intermittent versus continuous androgen deprivation therapy.

Higano CS.

J Natl Compr Canc Netw. 2014 May;12(5):727-33. Review.

PMID:
24812139
10.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group..

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
11.

Safety and tolerability of intermittent androgen deprivation therapy: a literature review.

Gruca D, Bacher P, Tunn U.

Int J Urol. 2012 Jul;19(7):614-25. doi: 10.1111/j.1442-2042.2012.03001.x. Epub 2012 Mar 21. Review.

12.

A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.

Kratiras Z, Konstantinidis C, Skriapas K.

Int Braz J Urol. 2014 Jan-Feb;40(1):3-15; discussion 15. doi: 10.1590/S1677-5538.IBJU.2014.01.02. Review.

13.

The role of intermittent androgen suppression in biochemically recurrent or newly diagnosed metastatic prostate cancer.

Crook J.

Curr Opin Support Palliat Care. 2013 Sep;7(3):258-64. doi: 10.1097/SPC.0b013e328363602e. Review.

PMID:
23912384
14.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
15.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.

Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Review.

PMID:
23628492
16.

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.

Calais da Silva F, Calais da Silva FM, Gonçalves F, Santos A, Kliment J, Whelan P, Oliver T, Antoniou N, Pastidis S, Marques Queimadelos A, Robertson C.

Eur Urol. 2014 Aug;66(2):232-9. doi: 10.1016/j.eururo.2013.03.055. Epub 2013 Apr 4.

PMID:
23582949
17.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
18.

Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.

Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL.

J Urol. 2017 May;197(5):1251-1257. doi: 10.1016/j.juro.2016.12.022. Epub 2016 Dec 16.

PMID:
27993663
19.

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.

Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.

PMID:
19249153
20.

Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.

Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL; Finnprostate Group..

Scand J Urol. 2014 Dec;48(6):513-22. doi: 10.3109/21681805.2014.901410. Epub 2014 Mar 31.

PMID:
24679247

Supplemental Content

Support Center